On Monday, Shares of Celgene Corporation (NASDAQ:CELG), gained 1.13% to $114.75.
Celgene Corporation declared that results from a multicenter, randomized, placebo-controlled phase II trial (BCT-001) of apremilast (Otezla®) in patients with Behçet’s disease were published in the April 16 issue of The New England Journal of Medicine. Behçet’s disease is a rare, chronic inflammatory disorder characterized by recurrent oral and genital ulcers, which are considered a hallmark of the disease. Joint inflammation and recurrent skin and eye lesions may also occur.
Findings from this study, counting the primary endpoint (reduction in mean number of oral ulcers following 12 weeks of treatment), were initially presented at the European League against Rheumatism (EULAR) and the American College of Rheumatology (ACR) annual meetings in 2013 (P<0.001). In addition to the formerly stated results, the publication comprises findings that the median (min, max) number of oral ulcers was also reduced following 12 weeks of treatment with apremilast contrast with placebo (0.0 (0, 6) vs. 2.0 (0, 13), respectively).
Findings from the full 24-week treatment phase were also comprised of in the publication. After 12 weeks, patients in the placebo group were crossed over to apremilast treatment, and those in the apremilast arm continued treatment. For those treated with apremilast for the full 24 weeks, the decrease in the mean number of oral ulcers was evident by week 2 (0.3 at week 2 vs. 2.7 at baseline) and this decrease was sustained through week 24 (0.6). In the placebo arm, the mean number of oral ulcers was 2.9 at baseline and 1.7 at week 2. At week 24, following 12 weeks of apremilast treatment, the mean number of oral ulcers in the placebo group was 0.4.
A decrease in pain associated with oral ulcers paralleled this decrease in ulcers over time. Mean pain scores, measured using a visual analog scale, reduced from 54.3 at baseline to 12.0 at week 2 and 9.7 at week 24. In the placebo arm, pain scores were 51.7 at baseline and 29.8 at week 2. At week 24, following 12 weeks of apremilast treatment, mean pain score in this group was 9.7.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Shares of International Paper Company (NYSE:IP), gained 1.11% to $54.65, during its last trading session.
International Paper Company, Chairman and Chief Executive Officer Mark S. Sutton will speak at the Goldman Sachs Basic Materials Conference on May 20, 2015, in New York City. The fireside chat is planned to start at 11:10am ET at the Goldman Sachs Conference Center.
International Paper Company operates as a paper and packaging company in North America, Europe, Latin America, Russia, Asia, Africa, and the Middle East. The company operates through three segments: Industrial Packaging, Printing Papers, and Consumer Packaging.
At the end of Monday’s trade, Shares of Nabors Industries Ltd. (NYSE:NBR), gained 1.09% to $14.88.
Nabors Industries, invites interested parties to join Anthony G. Petrello , Chairman and Chief Executive Officer and William Restrepo , Chief Financial Officer, Wednesday, April 22, 2015 at 10:00 a.m. Central Time for a discussion of operating results for the first quarter 2015. Nabors will release earnings after the market closes on April 21, 2015 .
Nabors Industries Ltd., together with its auxiliaries, provides drilling and rig services. The company offers rig instrumentation, optimization software, and directional drilling services. It also provides completion, life-of-well maintenance, and plugging and abandonment of a well.
Finally, Chevron Corporation (NYSE:CVX), ended its last trade with 1.08% gain, and closed at $110.29.
Chevron Corporation, will hold its quarterly earnings conference call on Friday, May 1, 2015, at 11:00 a.m. ET (8:00 a.m. PT).
Conference Call Information:
Date: Friday, May 1, 2015
Time: 11:00 a.m. ET / 8:00 a.m. PT
Dial-in # (Listen-only mode): 703-639-1116 / 866-219-5256
Conference ID #: 1654253.
Chevron Corporation, through its auxiliaries, engages in the petroleum, chemicals, and power and energy operations worldwide. The company operates in two segments, Upstream and Downstream.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
